tiprankstipranks
Advertisement
Advertisement

GENB Stock Latest News

Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright
The FlyGenerate Biomedicines price target raised to $30 from $25 at H.C. Wainwright
13d ago
GENB
Generate Biomedicines falls -16.7%
PremiumThe Fly
Generate Biomedicines falls -16.7%
15d ago
GENB
Generate Biomedicines falls -11.0%
PremiumThe Fly
Generate Biomedicines falls -11.0%
15d ago
GENB
Generate Biomedicines rises 17.7%
PremiumThe Fly
Generate Biomedicines rises 17.7%
16d ago
GENB
Generate Biomedicines Reaffirmed at Buy as GB-0895 Progress and Cash Runway Support Unchanged $25 Price Target
PremiumRatings
Generate Biomedicines Reaffirmed at Buy as GB-0895 Progress and Cash Runway Support Unchanged $25 Price Target
1M ago
GENB
Generate Biomedicines reports Q2 EPS (52c), consensus (49c)
PremiumThe FlyGenerate Biomedicines reports Q2 EPS (52c), consensus (49c)
1M ago
GENB
Generate Biomedicines falls -9.5%
Premium
The Fly
Generate Biomedicines falls -9.5%
2M ago
GENB
LLY, COIN, HOOD, and ROKU Stocks in Focus: Cathie Wood Sells Winners and Buys New Catalysts — 6/18/26
Premium
Market News
LLY, COIN, HOOD, and ROKU Stocks in Focus: Cathie Wood Sells Winners and Buys New Catalysts — 6/18/26
3M ago
LLY
XYZ
Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley
PremiumThe Fly
Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley
4M ago
GENB
Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
PremiumThe Fly
Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
4M ago
GENB
Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M
PremiumThe Fly
Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M
4M ago
GENB
Generate Biomedicines initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Generate Biomedicines initiated with a Buy at H.C. Wainwright
5M ago
GENB
PremiumRatingsBuy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
5M ago
GENB
Premium
Ratings
Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating
6M ago
GENB
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
6M ago
GENB
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
6M ago
GENB
Generate Biomedicines initiated with a Buy at Guggenheim
PremiumThe Fly
Generate Biomedicines initiated with a Buy at Guggenheim
6M ago
GENB
Generate Biomedicines initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Generate Biomedicines initiated with an Overweight at Morgan Stanley
6M ago
GENB
Generate Biomedicines initiated with an Overweight at Piper Sandler
PremiumThe Fly
Generate Biomedicines initiated with an Overweight at Piper Sandler
6M ago
GENB
Generate Biomedicines initiated with a Buy at Goldman Sachs
PremiumThe FlyGenerate Biomedicines initiated with a Buy at Goldman Sachs
6M ago
GENB
Opening Day: Janus Living opens at $23.50 after upsized IPO
Premium
The Fly
Opening Day: Janus Living opens at $23.50 after upsized IPO
6M ago
DOC
JAN
Opening Day: Generate Biomedicines makes public debut
Premium
The Fly
Opening Day: Generate Biomedicines makes public debut
6M ago
FPS
SGP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >